Efficacy of elobixibat for elderly patients with chronic constipation in a clinic

Table 2 Comparison of patient backgrounds by age, n (%)

	< 65 years old	≥ 65 years old	P value
Number of patients	35	45
Sex
Male	12 (34.3)	17 (37.8)	0.8171
Female	23 (65.7)	28 (62.2)	0.8171
Age	52.563 ± 9.648	76.023 ± 6.341	< 0.001
Pre-elobixibat defecation count/1-week frequency	2.167 ± 0.732	2.003 ± 0.733	0.9631
Pre-elobixibat Bristol Stool Form Scale/1-week score	2.286 ± 0.742	2.217 ± 0.758	0.8960
Number of drugs to relieve constipation before elobixibat administration
0	11 (31.4)	17 (37.8)	0.6397
1 magnesium oxide tablet	13 (37.1)	19 (42.2)	0.8183
2 magnesium oxide tablets + sennoside	7 (20)	13 (28.9)	0.0536
Comorbidity
Hypertension	10 (28.6)	28 (62.2)	0.0035
Hyperlipidemia	8 (22.9)	28 (62.2)	< 0.001
Diabetes mellitus	9 (25.7)	26 (57.8)	< 0.001
Cerebrovascular disease	5 (14.3)	11 (24.4)	0.3987
Chronic respiratory disease	3 (8.6)	10 (22.2)	0.1319
Cardiac disease	5 (14.3)	17 (37.8)	0.0241
Chronic hepatic disease	5 (14.3)	13 (28.9)	0.1775
Chronic renal disease	1 (2.9)	9 (20)	0.0370
Malignant disease	2 (7.7)	4 (8.9)	0.6945
Post cholecystectomy	6 (17.1)	12 (26.7)	0.4203